Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
17 hedge funds and large institutions have $2.86M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 7 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
11% less funds holding
Funds holding: 19 → 17 (-2)
22% less capital invested
Capital invested by funds: $3.67M → $2.86M (-$805K)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$631K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$246K |
| 3 |
Renaissance Technologies
New York
|
+$116K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$29.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.28M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$147K |
| 3 |
Millennium Management
New York
|
-$137K |
| 4 |
Goldman Sachs
New York
|
-$74K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21K |
FRTX Hedge Fund Activity: Q3 2020 in Review
17 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2020, worth a combined $2.86M — down 22% from $3.67M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FRTX and 5 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $631K. The largest seller was CVI Holdings, exiting entirely with an estimated $1.28M sold.
- 17 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2020, down from 19 in Q2 2020.
- Funds reported $2.86M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2020, down 22% quarter-over-quarter.
- 5 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2020 and 7 closed out, a net change of -2 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2020 was Sabby Management, an estimated $631K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2020 was CVI Holdings, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2020.